Skip to main content
    P

    Prime Medicine, Inc. Common Stock (PRME)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $4.65
    +0.20 (+4.49%)

    Market Cap: $807.13M

    Last updated: Nov 06, 2026 at 4:13 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    31%(5/16)
    Avg Surprise
    -19.78%
    Streak
    1 Q

    Upcoming Estimates

    Period ending Dec 31, 2026
    EPS Consensus$-0.20
    Range$-0.37 - $-0.06
    14 analysts
    Revenue Consensus
    $6M
    Range$-1085130 - $50M
    13 analysts
    Last 12 of 19 reported quarters and 1 upcoming estimate
    PeriodReportedEst.RangeSurpriseB/MAnalystsRevisionsYoY
    Dec 26EST
    		-$-0.20$-0.37 - $-0.06--14--
    Sep 26
    Reported Nov 6
    		$N/A$-0.23$-0.28 - $-0.19N/ABeat13
    1
    1
    30d
    		-
    Jun 26
    Reported Aug 6
    		$-0.24$-0.24$-0.29 - $-0.18+0.00%Beat13
    1
    1
    30d
    		+41.5%
    Mar 26
    Reported May 7
    		$-0.28$-0.25$-0.28 - $-0.19-12.00%Miss11
    2
    2
    30d
    		+30.0%
    Dec 25
    Reported Mar 3
    		$-0.24$-0.26$-0.31 - $-0.19+6.90%Beat11
    2
    5
    30d
    		+22.6%
    Sep 25
    Reported Nov 7
    		$-0.32$-0.25$-0.33 - $-0.21-28.00%Miss10
    8
    0
    30d
    		+27.3%
    Jun 25
    Reported Aug 7
    		$-0.41$-0.36$-0.42 - $-0.26-13.89%Miss10
    1
    0
    30d
    		+10.9%
    Mar 25
    Reported May 8
    		$-0.40$-0.31$-0.35 - $-0.18-29.03%Miss8
    2
    1
    30d
    		+9.1%
    Dec 24
    Reported Feb 28
    		$-0.31$-0.49$-0.66 - $-0.08+36.73%Beat10
    7
    1
    30d
    		+56.9%
    Sep 24
    Reported Nov 12
    		$-0.44$-0.42$-0.48 - $-0.35-4.76%Miss11
    1
    0
    30d
    		+20.0%
    Jun 24
    Reported Aug 8
    		$-0.46$-0.39$-0.43 - $-0.37-17.95%Miss12
    No revisions (30d)
    		+2.1%
    Mar 24
    Reported May 10
    		$-0.44$-0.46$-0.57 - $-0.41+4.35%Beat9
    No revisions (30d)
    		+0.0%
    Dec 23
    Reported Mar 1
    		$-0.72$-0.51$-0.58 - $-0.44-41.18%Miss8
    No revisions (30d)
    		-28.6%

    Key Metrics

    Valuation
    P/E Ratio-4.31EV/EBITDAN/A
    Price/FCF-5.25xFCF Yield-19.03%
    Profitability
    Profit Margin0.00%Operating Margin-3751.00%
    ROE-373.30%ROICN/A
    Financial Health
    Debt/Equity0.00xInterest CoverageN/A
    Current Ratio3.05xQuick Ratio3.05x
    Trading Statistics
    Beta2.15Avg Volume5.52M
    52-Week High$5.9152-Week Low$2.67

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$4.63
    SMA 20$4.12
    SMA 50$3.65
    SMA 200$3.51
    EMA 10$4.52
    EMA 20$4.24
    EMA 50$3.82
    EMA 200$3.53

    MACD

    Line: 0.35Signal: 0.32Hist: 0.03

    ADX

    ADX: 34.4+DI: 34.0-DI: 20.0

    Aroon & PSAR

    Aroon Up76.0
    Aroon Down4.0
    PSAR$4.02

    Bollinger Bands

    Upper Band$5.42
    Lower Band$2.82
    %B Position6298%(Upper)
    Band Width0.70

    RSI (14-Day)

    Neutral
    57.3

    Momentum Oscillators

    Stoch %K51.8
    Stoch %D53.0
    Williams %R-49.8
    ROC (10d)26.7%
    Momentum0.98
    CCI (20d)58.0
    MFI (14d)68.1

    Volatility Measures

    ATR (14d)$0.46(9.9%)
    StdDev (20d)0.65
    Hist Vol157.0%(High)

    Volume Flow

    VWAP$4.60
    OBV4.5M
    AD Line-46.1M
    CMF (20d)0.047

    Volume Metrics

    Avg Vol (20d)5.3M
    Vol Ratio0.6x
    VWMA (20d)$4.34

    Pivot Points

    R3$5.42
    R2$5.16
    R1$4.81
    Pivot Point$4.55
    S1$4.20
    S2$3.94
    S3$3.59

    Advanced Oscillators

    TSI18.83
    Ultimate Osc38.8
    KST357.84

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$1.15M$856,000$838,000$1.23M$1.11M$1.45M$2.18M$209,000$0$591,000$25.69M$0
    Cost of Revenue$0$0$1.88M$0$0$0$1.72M$0$0$0$1.25M$0
    Gross Profit$1.15M$856,000$838,000$1.23M$1.11M$1.45M$2.18M$209,000$0$591,000$-1,247,000$0
    Operating Expenses$44.44M$51.51M$49.45M$55.20M$54.49M$53.85M$46.41M$54.44M$55.67M$48.93M$68.04M$51.46M
    R&D$33.40M$34.10M$34.71M$43.99M$41.38M$40.56M$34.10M$40.34M$43.07M$37.77M$41.46M$40.97M
    SG&A$11.04M$17.41M$14.74M$11.21M$13.12M$13.28M$12.30M$14.10M$12.60M$11.16M$13.08M$10.49M
    Operating Income$-43,285,000$-50,654,000$-48,608,000$-53,973,000$-53,377,000$-52,392,000$-44,222,000$-54,232,000$-55,672,000$-48,341,000$-68,043,000$-51,459,000
    Interest Income$788,000$1.02M$1.08M$1.14M$743,000$1.18M$1.54M$697,000$611,000$676,000$0$410,000
    Interest Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Income Before Tax$-42,109,000$-49,122,000$-46,079,000$-50,582,000$-52,591,000$-51,890,000$-42,276,000$-52,518,000$-55,461,000$-45,627,000$-65,643,000$-50,816,000
    Income Tax Expense$0$0$0$0$0$0$0$0$-134,000$134,000$0$-108,000
    Net Income$-42,109,000$-49,122,000$-46,079,000$-50,582,000$-52,591,000$-51,890,000$-42,276,000$-52,518,000$-55,327,000$-45,761,000$-65,643,000$-50,708,000
    EBITDA$-41,424,000$-48,718,000$-46,074,000$-50,416,000$-51,881,000$-51,536,000$-42,242,000$-52,527,000$-55,938,000$-45,663,000$-67,250,000$-50,907,000
    EBIT$-42,897,000$-50,143,000$-47,162,000$-51,723,000$-53,334,000$-53,072,000$-43,814,000$-53,215,000$-56,072,000$-46,303,000$-67,409,000$-51,226,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about PRME

    News

    Jones Trading initiates Prime Medicine stock coverage with buy rating By Investing.com

    Jones Trading has initiated coverage on Prime Medicine Inc. (NASDAQ:PRME) with a Buy rating and a $6.00 price target...

    Investing.com UK•11/5/26•Bullish

    Jones Trading Assumes Prime Medicine (PRME) at Buy

    Jones Trading analyst Catherine Novack has initiated coverage on Prime Medicine (NASDAQ: PRME) with a Buy rating and a $6.00 price target...

    StreetInsider•11/5/26•Bullish

    Prime Medicine (PRME) Stock Price, Chart & Analysis

    This article provides a detailed analysis of Prime Medicine (PRME) stock, including its current price, market capitalization, quality score, and financial figures. It highlights the company's lack of profitability...

    www.debelegger.nl•11/2/26•Somewhat-Bearish

    Prime Medicine doses first patient in Wilson disease editing trial

    Prime Medicine has dosed the first patient in a Phase 1/2 clinical trial for PM577a, an experimental gene-editing treatment for Wilson disease targeting the H1069Q DNA variant in liver cells. This marks a significant...

    FindArticles•11/1/26•Somewhat-Bullish

    Wall Street Zen Upgrades Prime Medicine (NASDAQ:PRME) to "Hold"

    Wall Street Zen has upgraded Prime Medicine (NASDAQ:PRME) from a "sell" to a "hold" rating, though the overall analyst consensus remains a "Moderate Buy" with an average price target of $7.47. Despite opening at $4.72...

    MarketBeat•11/1/26•Neutral

    PRME Valuation and Fair Value

    P/E
    -4.3x
    P/FCF
    -5.3x
    P/B
    20.7x
    See GNG's fair value

    PRME Profitability: Margins, ROIC and FCF

    Gross margin
    100.0%
    Operating margin
    -3751.0%
    Net margin
    0.0%
    ROE
    -373.3%
    FCF yield
    -19.0%

    PRME Competitors

    CompanyTicker
    Beta Bionics, Inc. Common StockBBNX
    Esperion Therapeutics IncESPR
    Rigel Pharmaceuticals IncRIGL
    Phreesia IncPHR
    Ardelyx IncARDX
    Varex Imaging CorpVREX
    Inventiva SaIVA
    Ginkgo Bioworks HoldingsDNA

    Sector: Healthcare

    PRME Analyst Ratings

    Consensus
    Buy
    Analysts
    14
    Strong Buy
    1
    Buy
    10
    Hold
    3
    Sell
    0
    Strong Sell
    0

    PRME Bull Case vs Bear Case

    Bull case

    • 78.6% of PRME's analyst ratings are Buy or Strong Buy.

    Bear case

    • PRME beat EPS estimates in 25.0% of its last 8 reported quarters.

    PRME Earnings: Beat Rate and Next Report

    Beat rate
    2 of 8 quarters (25.0%)
    Average surprise
    -5.5%
    EPS estimate (fiscal period ending Dec 31, 2026)
    $-0.20

    PRME Earnings Date

    PRME reports Mar 1, 2027, before the open. The date is estimated.

    PRME ETF Holders

    GNG tracks 7 ETFs that hold PRME. The largest weights:

    1. ARK Genomic Revolution ETF (ARKG), 1.82% of the fund
    2. State Street SPDR S&P Biotech ETF (XBI), 0.19% of the fund
    3. iShares Biotechnology ETF (IBB), 0.03% of the fund
    4. iShares Russell 2000 ETF (IWM), 0.01% of the fund
    5. Vanguard Russell 2000 Index Fund ETF Shares (VTWO), 0.01% of the fund
    Open the ETF Stock Exposure tool for PRME

    Frequently Asked Questions About PRME

    When does PRME report earnings?

    Prime Medicine, Inc. Common Stock (PRME) is expected to report earnings on Mar 1, 2027.

    Does PRME pay dividends?

    Prime Medicine, Inc. Common Stock (PRME) does not currently pay a regular dividend.

    What is PRME's market cap?

    Prime Medicine, Inc. Common Stock (PRME) has a market capitalization of $807.13M with a current stock price of $4.65.

    Related stocks

    Sector: Healthcare

    All stocks starting with P

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In